Avanir Pharmaceuticals Inc. reported positive results from one of two planned pivotal trials testing Neurodex in pseudobulbar affect, a somewhat rare tragedy/comedy neurological affliction that affects up to an estimated 1 million people in the U.S. each year. (BioWorld Today) Read More
